medigraphic.com
ISSN 0210-5187 (Electronic)

2004, Number 6

<< Back Next >>

Med Cutan Iber Lat Am 2004; 32 (6)

New Antifungals and their use in Dermatology

Escobar CM, Zuluaga A

Language: Spanish
References: 39
Page: 231-242
PDF size: 268.56 Kb.


ABSTRACT

After the discovery of the first antifungal therapy five decades ago, these therapeutic agents have gone through a constant development. Since these agents are associated with increase in resistance, toxicity, adverse drug interactions as well as limited spectrum of activity, it is that new antifungal agents have been created: second generation triazoles (voriconazole, posaconazole, ravuconazole, albaconazole), echinocandin (caspofungin, anidulafungin, micafungin) among others.Voriconazole is an FDA approved medication for the treatment for invasive and resistant aspergillus infection. The echinocandins have a high selectivity against Candida spp., Aspergillus spp., and Pneumocistis carinii.In dermatology, voriconazole has been used successfully for treatment of dermatophytes, deep mycoses caused by Fonseca pedrosoi, Paecilomyces lilacinus and Scedosporium apiospemum. Ravuconazole has been used as well with good results for onychomycoses by dermatophytes and caspofungin for treatment of Aspergillus resistant to Anfotericin B.


REFERENCES

  1. Arathoon EG. Clinical efficacy of echinocandin antifungals. Current opinion in infectious diseases 2001; 14: 685-91.

  2. Singh N. Changing spectrum of invasive candidiasis and its therapeutic implications. Clin Microbiol Infect 2001; 7: 1-7.

  3. Maertens JA. History of the development of azole derivates. Clin Microbiol Infect 2004; Suppl. 1: 1-10.

  4. Tkacz JS, DiDomenico B. Antifungals: what is in the pipeline? Current opinión in Microbiology 2001; 4: 540-5.

  5. WE Dismukes, PG Pappa, JD Sobel. Clinical Mycology, Oxford University Press, New York, NY 2003.

  6. Sanati H, Belanger P, Fratti R, Ghannoum M. A new triazol, voriconazol (UK-109,496) blocks sterol biosyhtnesis in Candida albicans and Candida Krusei. Antimicrob Agents chemother 41: 2467-92, 1997.

  7. Barone JA, Koh JG, Bierman RH, Colaizzi JL, et al. Food interaction and steady state pharmacokinetics of itraconazol capsules in healthy male volunteers. Antimicrob Agents chemother 1993; 37: 778-84.

  8. Debeule K, Van Gestel J. Pharmacology of itraconazol. Drugs 2001; 61: 26-37.

  9. Ito S, Koren G. Comment: possible mechanism of digoxina-itraconazole interaction. Ann Pharmacother 1997; 31: 1091-2.

  10. Pfaller MA, Zhang J, Messer SA, Brandt ME, et al. In vitro activities of voriconazole, fluconazole, and itraconazole against 544 clinical islates of Cryptococcus neoformans from United States and Africa. Antimicrob Agents Chemother 1999; 43: 169-71.

  11. Sheehan DJ, Hitchcock Ca, Sibley CM. Current and emerging azole antifungal agents. Clin Microbiol Rev 1999; 12: 40-79.

  12. Pfaller MA, Messer S, Hollis RJ, Jones RN, et al. In vitro susceptibilities of Candida blood stream isolates to the new triazole antifungal agents BMS-207147, SCH 56592, and voriconazol. Antimicrob Agents Chemother 1998; 42: 3242-4.

  13. Frank CO, Alistair JP, Brown, Neil AR. Antifungal agents: mechanism of action. TRENDS in microbiology 2003; 11: 272-9.

  14. Gupta AK, Tomas E. New antifungal agents. Dermatol Clin 2003; 21: 565-76.

  15. Sugar AM, Liu XP. In vitro and in vivo activities of SCH 56592 against Blastomyces dermatitidis. Antimicrob Agents Chemother 1996; 40: 1910-3.

  16. Lutz JE, Clemons KV, Aristizabal BH, Stevens DA. Activity of the triazole SCH 56592 against disseminated murine coccidioidomycosis. Antimicrob Agents Chemother 1999; 41: 1558-61.

  17. Cacciapuoti A, Loebenberg D, Corcoran E, Menzel F, et al. In vivo and in vitro activities of SCH 56592 (posaconazol), a new triazole antifungal agent, against Aspergillus and Candida. Antimicrob Agents Chemother 2000; 44: 2017-22.

  18. Garau M, Pereiro M, del Palacio A. In vitro susceptibilities of Malassezia species to a new triazole, albaconazol (UR-9825), and other antifungal compounds. Antimicrob Agents Chemother 2003; 47: 2342-4.

  19. David S. McKinsey. Making best use oft the newer antifungal drugs. Infect Med 2003; 20: 392-9.

  20. Hector FR. Compounds active against cell walls of medically important fungi. Clin Microbiol Rev 1993; 6: 1-21.

  21. Onishi J, Mainz M, Thompson J, et al. Discovery of novel antifungal (1, 3) Beta-D glucan synthasa inhibitors. Antimicrob Agents Chemother 2000; 44: 368-77.

  22. Nilius AM, Raney PM, Hensey-Rudloff DM, et al. In vitro activity of A-192411.29, a novel antifungal lipopeptide. Antimicrob Agents Chemother 2000; 44: 1224-46.

  23. Keating GM, Jarvis B. Caspofungin. Drugs 2001; 61: 1121-9.

  24. Bachmann SP, Patterson TF, Lopéz-Ribot JL. In vitro activity of caspofungina (MK0991) against Candida albicans clinical islates displaying different mechanism of azole resistance. J Clin Microbiol 2002; 40: 2228-30.

  25. Bartizal K, Gill CJ, Abruzzo GK, Flattery AM, et al. In vitro preclinical evaluation studies with the echinocandin antifungal MK 0991 (L-743,872). Antimicrob Agents Chemother 1997; 41: 2326-32.

  26. Villanueva A, Arathoon EG, Gottuzzo E, Berman RS, et al. A randomized double blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin Infect Dis 2001; 33: 1529-35.

  27. Stevens DA. Drug interaction studies of a glucan synthetase inhibitor (LY 303366) and a chitin synthetase inhibitor (Nikkomicin Z) for inhibition and killing of fungal pathogens. Antimicrob Agents Chemother 2000; 44:2547-8.

  28. Zuluaga A, Tabares AM, Arango M, Robledo MA, et al. Importancia creciente de los géneros Fusarium y Sytalidium como agentes de onicomicosis. Rev Asoc Col Dermatol 2001; 9: 593-9.

  29. De Bedout C, Tabares AM, Restrepo A, Arango M, et al. Especies de Cándida aisladas de lesiones ungueales y su sensibilidad in vitro al fluconazol (1999-2001). Rev Asoc Col Dermatol 2003: 11:325-31.

  30. Serrano-Martino MdelC, Pemán J, Martín-Mazuelos E, Valverde-Conde A, Claro RM. Actividad in vitro de voriconazol y otros tres antifúngicos frente a dermatofitos. Enferm Infecc Microbiol Clin 2003; 21: 484-7.

  31. Hamaza SH, Mercado PJ, Skelton HG, Smith KJ. An inusual dematiaceos fungal infection of the skin caused by Fonseca pedrosoi: a case report and review of the literature. J Cutan Path 2003; 30: 340.

  32. Hilmarsdottir I, Thrsteinsson SB, Asmundsson P, Bodvarsson M, et al. Cutaneus infection caused by Paecilomyces lilacinus in a renal transplant patient: Treatment with Voricnazol. Scand J Infect Dis 2000; 32: 331-2.

  33. Bosma F, Voss A, van Hamersvelt HW, de Sévaux RGL, et al. Two cases of subcutaneous Scedosporium apiospermum infection treated with voriconazol. Clin Microbiol Infect 2003; 9: 750-3.

  34. Fung-Tomc JC, Huczko E, Minassian B, Bonner DP. In vitro activity of a new oral triazole. BMS-207147 (ER-30346). Antimicrob Agents Chemother 1998; 42:313-8.

  35. Hata K, Kimura J, Miki H, Toyosawa T, et al. In vitro and in vivo antifungal activities of ER-30346, a novel oral triazole with a broad antifungal spectrum. Antimicrob Agents Chemother 1996; 40: 2237-42.

  36. Garau M, Pereiro M, Del Palacio A. In vitro susceptibilities of Malassezia Species to a New Triazole, Albaconazole (UR-9825), and Other Antifungal Compounds. Antimicrob Agents Chemother 2003; 47: 2342-4.

  37. Koss T, Bagheri B, Zeana C, Romagnoli MF et al. Amphotericin B-resistent Aspergillus flavus infection successfully treated with caspofungina novel antifungal agent. J Am Acad Dermatol 2002; 46: 945-7.

  38. Mcginnis MR, Nordoff N, Li RK, Pasarell L. Sporothrix schenckii sensitivity to voriconazole, itraconazole and amphotericin B. Medical Mycology 2001; 39: 369-71.

  39. Durand-Joly I, Alfandari S, Benchikh Z, Rodrigue M, et al. Successful Outcome of Disseminated Fusarium Infection with Skin localization Treated with Voriconazole and Amphotericin B-Lipid Complex in a Patient with Acute Leukemia. J of Clin Microb 2003; 41: 4898-900.




2020     |     www.medigraphic.com